Vertex Pharmaceuticals (VRTX) to Release Earnings on Monday

Vertex Pharmaceuticals (NASDAQ:VRTX) will release its earnings data after the market closes on Monday, May 6th. Analysts expect Vertex Pharmaceuticals to post earnings of $3.61 per share for the quarter. Vertex Pharmaceuticals has set its FY 2024 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The company had revenue of $2.52 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the company posted $3.33 EPS. On average, analysts expect Vertex Pharmaceuticals to post $15 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $397.48 on Monday. Vertex Pharmaceuticals has a 52 week low of $320.01 and a 52 week high of $448.40. The firm has a 50 day moving average of $411.60 and a two-hundred day moving average of $399.17. The stock has a market capitalization of $102.73 billion, a PE ratio of 28.62, a P/E/G ratio of 1.87 and a beta of 0.35. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the transaction, the executive vice president now directly owns 74,364 shares in the company, valued at $31,250,727.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at $23,755,762.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Amit Sachdev sold 3,222 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the transaction, the executive vice president now owns 74,364 shares in the company, valued at $31,250,727.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on VRTX. JPMorgan Chase & Co. raised their price objective on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. UBS Group reduced their price objective on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Wells Fargo & Company raised their price objective on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Wolfe Research began coverage on shares of Vertex Pharmaceuticals in a report on Thursday, February 15th. They issued an “outperform” rating and a $515.00 price objective on the stock. Finally, Truist Financial raised their price objective on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $429.45.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.